{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:17:33Z","timestamp":1794410253519,"version":"4.9.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.healun.2025.05.013","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T16:17:10Z","timestamp":1748621830000},"page":"1569-1580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy intravenous istaroxime up to 60\u00a0hours for patients with pre-cardiogenic shock"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-7753","authenticated-orcid":false,"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-7871","authenticated-orcid":false,"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Tyci\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Novosadova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7701-0878","authenticated-orcid":false,"given":"Gaurav","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianela","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luz","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zymli\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Simonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2025.05.013_bib1","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2025.05.013_bib2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/CRD.0000000000000237","article-title":"Precardiogenic shock: a new clinical entity","volume":"27","author":"Singh","year":"2019","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.healun.2025.05.013_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ejhf.2449","article-title":"Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause\u2014the cardiogenic shock score","volume":"24","author":"Beer","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib5","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1002\/ehf2.13826","article-title":"Epinephrine infusion during venoarterial extracorporeal membrane oxygenation support for cardiogenic shock: simply inefficient or deleterious?","volume":"9","author":"Guihaire","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib6","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","article-title":"Treatments targeting inotropy","volume":"40","author":"Maack","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.healun.2025.05.013_bib7","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ehf2.13893","article-title":"Norepinephrine use in cardiogenic shock patients is associated with increased 30 day mortality","volume":"9","author":"Lu","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ejhf.3162","article-title":"Medical therapy of cardiogenic shock: contemporary use of inotropes and vasopressors","volume":"26","author":"Riccardi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12471-019-01351-7","article-title":"Haemodynamic efficacy of microaxial left ventricular assist device in cardiogenic shock: a systematic review and meta-analysis","volume":"28","author":"van Dort","year":"2020","journal-title":"Neth Heart J"},{"key":"10.1016\/j.healun.2025.05.013_bib10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","article-title":"DanGer shock investigators. Microaxial flow pump or standard care in infarct-related cardiogenic shock","volume":"390","author":"M\u00f8ller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2025.05.013_bib11","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jacc.2019.02.051","article-title":"Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week","volume":"73","author":"Psotka","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2025.05.013_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1113\/jphysiol.2005.091801","article-title":"Sodium pump \u03b12 subunits control myogenic tone and blood pressure in mice","volume":"569","author":"Zhang","year":"2005","journal-title":"J Physiol"},{"key":"10.1016\/j.healun.2025.05.013_bib13","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/ejhf.1843","article-title":"Istaroxime in acute heart failure: the holy grail is at HORIZON?","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib14","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.jacc.2008.03.015","article-title":"Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure","volume":"51","author":"Gheorghiade","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2025.05.013_bib15","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/ejhf.1743","article-title":"Treatment with 24\u2009hours istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial","volume":"22","author":"Carubelli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2009.03.007","volume":"157","author":"Shah","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.healun.2025.05.013_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10557-011-6295-7","article-title":"Istaroxime: Is the remedy better than the disease?","volume":"25","author":"Farmakis","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.healun.2025.05.013_bib18","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S2213-2600(21)00172-7","article-title":"Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop","volume":"9","author":"Arrigo","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.healun.2025.05.013_bib19","first-page":"29","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Inter"},{"key":"10.1016\/j.healun.2025.05.013_bib20","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/ehf2.14510","article-title":"Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction","volume":"10","author":"Bertaina","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib21","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/ejhf.2629","article-title":"Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock\u2014a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC)","volume":"24","author":"Metra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cardfail.2023.03.020","article-title":"Safety and efficacy of istaroxime 1.0 and 1.5 \u00b5g\/kg\/min for patients with pre-cardiogenic shock","volume":"29","author":"Metra","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ehf2.15102","article-title":"Safety and efficacy of up to 60 hours of iv istaroxime in pre-cardiogenic shock patients: design of the SEISMiC trial","volume":"12","author":"Biegus","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i09","article-title":"sanon: An R package for stratified analysis with nonparametric covariable adjustment","volume":"67","author":"Kawaguchi","year":"2015","journal-title":"J Stat Softw"},{"key":"10.1016\/j.healun.2025.05.013_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.healun.2023.09.014","article-title":"Heart failure related cardiogenic shock: an ISHLT consensus conference content summary","volume":"43","author":"Kanwar","year":"2024","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2025.05.013_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ejhf.3082","article-title":"Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heart failure-related cardiogenic shock","volume":"26","author":"Sundermeyer","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ehf2.13859","article-title":"Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care","volume":"9","author":"Tomasoni","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(24)01448-X","article-title":"Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up","volume":"404","author":"Thiele","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2025.05.013_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2025.05.013_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/j.1875-9114.1997.tb03722.x","article-title":"Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good","volume":"17","author":"Varriale","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.healun.2025.05.013_bib31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1054\/jcaf.2001.24136","article-title":"A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure","volume":"7","author":"Loh","year":"2001","journal-title":"J Card Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0735-1097(87)80223-1","article-title":"Efficacy and safety of sustained (48\u2009hours) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study","volume":"9","author":"Anderson","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2025.05.013_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1074248418797357","article-title":"Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock","volume":"24","author":"Lewis","year":"2019","journal-title":"J Cardiovasc Pharm Ther"},{"key":"10.1016\/j.healun.2025.05.013_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.healun.2025.05.013_bib35","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2025.05.013_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.medin.2017.08.009","article-title":"Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis","volume":"42","author":"Fang","year":"2018","journal-title":"Med Intensiv (Engl Ed)"},{"key":"10.1016\/j.healun.2025.05.013_bib37","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ejhf.3025","article-title":"Impella and venoarterial extracorporeal membrane oxygenation in cardiogenic shock complicating acute myocardial infarction","volume":"25","author":"Bogerd","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2025.05.013_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41569-022-00796-5","article-title":"Temporary mechanical circulatory support devices: practical considerations for all stakeholders","volume":"20","author":"Salter","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.healun.2025.05.013_bib39","first-page":"1702","article-title":"Rates and impact of vascular complications in mechanical circulatory support","volume":"99","author":"Lemor","year":"2022","journal-title":"Catheter Cardiovasc Inter"},{"key":"10.1016\/j.healun.2025.05.013_bib40","first-page":"999","article-title":"Device-related complications after Impella mechanical circulatory support implantation: an IMP-IT observational multicentre registry substudy","volume":"10","author":"Ancona","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.healun.2025.05.013_bib41","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0002-8703(97)80014-2","article-title":"Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure","volume":"134","author":"Tsutamoto","year":"1997","journal-title":"Am Heart J"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825019771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825019771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:55:47Z","timestamp":1757771747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249825019771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1053249825019771"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2025.05.013","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy intravenous istaroxime up to 60\u00a0hours for patients with pre-cardiogenic shock","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2025.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Heart and Lung Transplantation. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}